12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Five Prime, UCB deal

UCB and Five Prime partnered to discover drug targets and therapeutics for fibrosis-related inflammatory diseases and CNS disorders. Under the deal, UCB and Five Prime will design assays to screen Five Prime's library of...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >